Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.

作者: Neil P Shah , Charles L Sawyers

DOI: 10.1038/SJ.ONC.1206942

关键词:

摘要: Philadelphia chromosome-associated leukemias are among the most well-understood human malignancies. The importance of BCR-ABL enzymatic activity in proliferation leukemic clone has been confirmed by high response rates these to ABL-selective tyrosine kinase inhibitor STI571, even advanced disease phases, which characterized increased genetic heterogeneity. Disease relapse observed a subset patients who had initially responded STI571. Evidence suggests that is restored majority cases acquired resistance. Molecular studies resistant leukemia cells isolated from have implicated domain point mutation as common mechanism Additionally, genomic amplification gene can occasionally be detected. This review will highlight mechanisms STI571 resistance clinical samples well preclinical models.

参考文章(13)
Philipp le Coutre, Elena Tassi, Marileila Varella-Garcia, Rossella Barni, Luca Mologni, Gonçalo Cabrita, Edoardo Marchesi, Rosanna Supino, Carlo Gambacorti-Passerini, Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. ,vol. 95, pp. 1758- 1766 ,(2000) , 10.1182/BLOOD.V95.5.1758.005A41_1758_1766
Michael W.N. Deininger, John M. Goldman, Nicholas Lydon, Junia V. Melo, The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells Blood. ,vol. 90, pp. 3691- 3698 ,(1997) , 10.1182/BLOOD.V90.9.3691
Christophe Barthe, Pascale Cony-Makhoul, Junia V Melo, Josy Reiffers François-Xavier Mahon, None, Roots of Clinical Resistance to STI-571 Cancer Therapy Science. ,vol. 293, pp. 2163a- 2163 ,(2001) , 10.1126/SCIENCE.293.5538.2163A
Wolf-K. Hofmann, Letetia C. Jones, Nathan A. Lemp, Sven de Vos, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann, H. Phillip Koeffler, Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. ,vol. 99, pp. 1860- 1862 ,(2002) , 10.1182/BLOOD.V99.5.1860
Mercedes E Gorre, Mansoor Mohammed, Katharine Ellwood, Nicholas Hsu, Ron Paquette, P Nagesh Rao, Charles L Sawyers, Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification Science. ,vol. 293, pp. 876- 880 ,(2001) , 10.1126/SCIENCE.1062538
Hagop Kantarjian, Charles Sawyers, Andreas Hochhaus, Francois Guilhot, Charles Schiffer, Carlo Gambacorti-Passerini, Dietger Niederwieser, Debra Resta, Renaud Capdeville, Ulrike Zoellner, Moshe Talpaz, Brian Druker, None, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia The New England Journal of Medicine. ,vol. 346, pp. 645- 652 ,(2002) , 10.1056/NEJMOA011573
Neil P. Shah, John M. Nicoll, Bhushan Nagar, Mercedes E. Gorre, Ronald L. Paquette, John Kuriyan, Charles L. Sawyers, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell. ,vol. 2, pp. 117- 125 ,(2002) , 10.1016/S1535-6108(02)00096-X
Catherine Roche-Lestienne, Valerie Soenen-Cornu, Nathalie Grardel-Duflos, Jean-Luc Laı̈, Nathalie Philippe, Thierry Facon, Pierre Fenaux, Claude Preudhomme, Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment Blood. ,vol. 100, pp. 1014- 1018 ,(2002) , 10.1182/BLOOD.V100.3.1014
A Hochhaus, S Kreil, AS Corbin, P La Rosée, MC Müller, T Lahaye, B Hanfstein, C Schoch, NCP Cross, U Berger, H Gschaidmeier, BJ Druker, R Hehlmann, Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. ,vol. 16, pp. 2190- 2196 ,(2002) , 10.1038/SJ.LEU.2402741